Form 4: Procept BioRobotics CEO Reza Zadno Sells Shares Under 10b5-1 Trading Plan

Procept BioRobotics CEO Reza Zadno sold a total of 26,420 shares of common stock on November 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Reza Zadno, the CEO of Procept BioRobotics, sold 26,420 shares of the company's common stock on November 13, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 8, 2024.
• The shares were sold in multiple transactions at varying prices, with weighted average prices reported for each block of sales.
• The sales resulted in a decrease in Zadno's direct holdings of Procept BioRobotics common stock from 258,445 to 232,025 shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock sales under a pre-arranged plan, which is neither particularly positive nor negative. It is a neutral event.

Negatives

• The CEO's sale of shares could be perceived negatively by some investors.

Risks

• The sale of shares by a key executive could potentially signal a lack of confidence in the company's future prospects, although this is mitigated by the pre-arranged trading plan.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and the use of 10b5-1 trading plans is a standard practice to avoid accusations of trading on non-public information. This filing is a routine disclosure of such activity.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the medical device industry like Procept BioRobotics.
• Similar filings are regularly made by executives at companies such as Intuitive Surgical (ISRG) and Stryker (SYK) when they sell shares under pre-arranged plans.
• The volume of shares sold is not unusual for an executive of a company of Procept's size.

Stakeholder Impact

• The sale of shares by the CEO could potentially cause a slight negative reaction from shareholders, although the pre-arranged nature of the sales mitigates this concern.

Key Dates

Keywords

insider trading, stock sale, Rule 10b5-1, Reza Zadno, Procept BioRobotics, PRCT, CEO, share sale